Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  carfilzomib
Find trials that include:  Any drugs shown
Results 1-25 of 35 for your search:
Start Over
Bortezomib or Carfilzomib with Lenalidomide and Dexamethasone in Treating Patients with Newly Diagnosed Multiple Myeloma
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: 18 and over
Trial IDs: E1A11, NCI-2012-02608, ECOG-E1A11, NCT01863550
A Study in Subjects With Relapsed and Refractory Multiple Myeloma Receiving Carfilzomib in Combination With Dexamethasone, Comparing Once-weekly Versus Twice-weekly Carfilzomib Dosing (ARROW)
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CFZ014, NCI-2015-01208, 2014-005325-12, NCT02412878
Lenalidomide with or without Carfilzomib and Dexamethasone in Treating Patients with Multiple Myeloma after Stem-Cell Transplant
Status: Not yet active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: IRB15-1286, NCI-2016-00079, NCT02659293
Carfilzomib, Pegylated Liposomal Doxorubicin Hydrochloride, and Dexamethasone in Treating Patients with Relapsed or Refractory Multiple Myeloma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 201102043, NCI-2011-00224, NCT01246063
A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: AMyC 10-MM-01, NCI-2012-01279, IST-CAR-521, PO-MM-PI-0034, NCT01464034
Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients with Relapsed or Refractory Multiple Myeloma
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: IRB12-1088, NCI-2012-01168, IRB12-1088-CR003, MMRC-048, MMRC# 048 / U Chicago protocol IRB#12-1088, NCT01665794
Carfilzomib, Lenalidomide and Rituximab in Treating Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2012-0188, NCI-2014-01201, NCI-2013-00117, NCT01729104
Carfilzomib and Melphalan before Stem Cell Transplant in Treating Patients with Multiple Myeloma
Status: Temporarily closed
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MC1185, NCI-2013-00550, NCT01842308
Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CRAB CTC 11-001, NCI-2014-02260, CAR-IST-553, NCI-2013-02243, NCT01941316
Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 74
Trial IDs: I 240813, NCI-2013-01784, NCT01959698
Study of the Bruton's Tyrosine Kinase Inhibitor in Combination With Carfilzomib (Kyprolis™) in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: PCYC-1119-CA, NCI-2014-00660, PCI-32765 [Sponsor], NCT01962792
Carfilzomib in Combination with Bendamustine Hydrochloride and Dexamethasone in Treating Patients with Newly Diagnosed Multiple Myeloma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: AAAJ2359, NCI-2014-02521, IRB-AAAJ2359, NCT02002598
Carfilzomib, Rituximab, and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Lymphoma
Status: Not yet active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CASE3413, NCI-2014-00249, NCT02073097
Carfilzomib in Preventing Relapse and Graft-versus-Host Disease in Patients with High-Risk Hematologic Malignancies Undergoing Donor Hematopoietic Cell Transplant
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: Over 18 to less than 65
Trial IDs: UMCC 2014.010, NCI-2014-01923, 2014.010, CR00046767, HUM00084170, NCT02145403
Study of Carfilzomib in Combination With Dexamethasone, Mitoxantrone, PEG-asparaginase, and Vincristine in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and under
Trial IDs: CFZ008, NCI-2014-02601, 2014-001633-84, NCT02303821
Carfilzomib, Romidepsin, and Lenalidomide in Treating Patients with Relapsed or Refractory B-cell and T-cell Lymphomas
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 14-179, NCI-2015-00109, NCT02341014
Carfilzomib, Lenalidomide, and Dexamethasone before and after Stem Cell Transplant in Treating Patients with Newly Diagnosed Multiple Myeloma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: IRB12-1725, NCI-2012-02023, MMRC-043, NCT01816971
Carfilzomib in Treating Patients With Multiple Myeloma in First Relapse or Refractory to First-Line Therapy
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: IUCRO-0414, NCI-2013-01771, NCT02020941
Carfilzomib in Treating Patients with Metastatic Hormone-Resistant Prostate Cancer That Has Progressed after Chemotherapy and Androgen Inhibitor Therapy
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 19 and over
Trial IDs: UAB1336, NCI-2015-00263, F130725012, NCT02047253
Carfilzomib in Treating Patients with Chronic Graft-Versus-Host Disease
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9228, NCI-2015-00809, 9228.00, NCT02491359
Selinexor, Carfilzomib, and Dexamethasone Versus Placebo, Carfilzomib, and Dexamethasone in Multiple Myeloma
Status: Not yet active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: KCP-330-015, NCI-2016-00172, NCT02628704
Carfilzomib Plus Panobinostat in Relapsed/Refractory Multiple Myeloma (MM)
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2010-0733, NCI-2011-00316, NCT01301807
KSP Inhibitor ARRY-520 and Carfilzomib in Treating Patients with Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2011-0144, NCI-2011-01120, NCT01372540
Carfilzomib with or without Romidepsin in Treating Patients with Stage IA-IVB Cutaneous T-Cell Lymphoma
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NU 12H06, NCI-2012-01952, IST-CAR-532, SP0021927, STU00071042, NCT01738594
A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CR103015, NCI-2014-02217, 2013-003491-12, 54767414MMY1001, NCT01998971
Start Over